A Merck sign hangs on the side of an office building in South San Francisco, California. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our ...

Merck and Cardiome Pharma Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation; Cardiome to Receive Initial Fee of US$60M and Up to $300M in Milestones ...

(RTTNews) - Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development collaboration to evaluate the combination of Exelixis' ...

“This collaboration underscores our belief in zanzalintinib’s potential to drive patient benefit in combination with immunotherapy or targeted therapy in HNSCC and RCC indications that have unmet ...